Test-of-cure stool cultures for traveler's diarrhea
- PMID: 3290233
- PMCID: PMC266517
- DOI: 10.1128/jcm.26.5.1047-1049.1988
Test-of-cure stool cultures for traveler's diarrhea
Abstract
Whether enteropathogens were eradicated or persisted in test-of-cure stool cultures from 251 patients with traveler's diarrhea, the durations of diarrhea were similar within the antimicrobial agent-treated (32 versus 33 h) and placebo-treated (82 versus 96 h) groups. Routine test-of-cure stool cultures can be useful for evaluating treatment failures and for assessing asymptomatic carriage of enteropathogens after treatment, but they are not mandated in the design of placebo-controlled antimicrobial treatment trials in traveler's diarrhea when the focus of the trial is clinical efficacy.
Similar articles
-
Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.Antimicrob Agents Chemother. 1992 Jan;36(1):87-91. doi: 10.1128/AAC.36.1.87. Antimicrob Agents Chemother. 1992. PMID: 1590705 Free PMC article. Clinical Trial.
-
Rifamycin SV MMX for the treatment of traveler's diarrhea.Expert Opin Pharmacother. 2017 Aug;18(12):1269-1277. doi: 10.1080/14656566.2017.1353079. Epub 2017 Jul 27. Expert Opin Pharmacother. 2017. PMID: 28697313 Review.
-
Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin.Antimicrob Agents Chemother. 1986 Nov;30(5):671-4. doi: 10.1128/AAC.30.5.671. Antimicrob Agents Chemother. 1986. PMID: 3800342 Free PMC article. Clinical Trial.
-
Spectrum of enteropathogens in cases of traveler's diarrhea that were detected using the FilmArray GI panel: New epidemiology in Japan.J Infect Chemother. 2021 Jan;27(1):49-54. doi: 10.1016/j.jiac.2020.08.009. Epub 2020 Aug 22. J Infect Chemother. 2021. PMID: 32839110
-
Evaluation and Management of Traveler's Diarrhea in Children.Pediatr Clin North Am. 2022 Feb;69(1):99-113. doi: 10.1016/j.pcl.2021.08.004. Pediatr Clin North Am. 2022. PMID: 34794679 Review.
Cited by
-
Rifaximin: a review of its use in the management of traveller's diarrhoea.Drugs. 2005;65(12):1697-713. doi: 10.2165/00003495-200565120-00011. Drugs. 2005. PMID: 16060706 Review.
-
Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations.J Travel Med. 2017 Apr 1;24(suppl_1):S6-S12. doi: 10.1093/jtm/taw090. J Travel Med. 2017. PMID: 28520997 Free PMC article. Review.
-
Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.J Travel Med. 2018 Jan 1;25(1):tay116. doi: 10.1093/jtm/tay116. J Travel Med. 2018. PMID: 30462260 Free PMC article. Clinical Trial.
-
Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.Antimicrob Agents Chemother. 1992 Jan;36(1):87-91. doi: 10.1128/AAC.36.1.87. Antimicrob Agents Chemother. 1992. PMID: 1590705 Free PMC article. Clinical Trial.
-
Rifamycin SV MMX®: A Review in the Treatment of Traveller's Diarrhoea.Clin Drug Investig. 2019 Jul;39(7):691-697. doi: 10.1007/s40261-019-00808-2. Clin Drug Investig. 2019. PMID: 31172447 Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical